SCHEMBL2837658

SCHEMBL2837658

COC(=O)C1=C[C@@H](O)C[C@H]1C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR4 O00206 1/20 0.37
KDM4E B2RXH2 8/20 0.35
ALDH1A1 P00352 8/20 0.35
GAA P10253 5/20 0.35
HPGD P15428 4/20 0.35
CASP1 P29466 4/20 0.35
CASP7 P55210 4/20 0.35
HSD17B10 Q99714 4/20 0.35
TSHR P16473 2/20 0.35
ATM Q13315 2/20 0.35
KCNH2 Q12809 1/20 0.34
GLA P06280 3/20 0.32
PTPN1 P18031 1/20 0.32
POLB P06746 3/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
MAPK1 P28482 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
SLC6A3 Q01959 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1101940 1.00 TLR4 (0.37) TLR4KDM4EALDH1A1GAAHPGD
SCHEMBL5741678 1.00 TLR4 (0.37) TLR4KDM4EALDH1A1GAAHPGD
SCHEMBL1101682 0.86 KCNH2 (0.37) TLR4KDM4EALDH1A1GAAHPGD
SCHEMBL20383516 0.86 KCNH2 (0.37) TLR4KDM4EALDH1A1GAAHPGD
SCHEMBL19110976 0.83 TLR4 (0.35) TLR4KDM4EALDH1A1GAAHPGD
SCHEMBL20378108 0.81 ALDH1A1 (0.34) TLR4KDM4EALDH1A1GAAHPGD
SCHEMBL20378185 0.79
SCHEMBL5487626 0.79
SCHEMBL19093191 0.79
SCHEMBL8284999 0.78 ALDH1A1 (0.40) TLR4KDM4EALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100166706-A1 HCV NS-3 SERINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2010-07-01 US disclosed
US-7700552-B2 Macrocyclic inhibitors of hepatitis C virus MEDIVIR AB (SE) 2010-04-20 US disclosed
US-7671032-B2 HCV NS-3 serine protease inhibitors MEDIVIR AB (SE) 2010-03-02 US disclosed
US-7659245-B2 Macrocylic inhibitors of hepatitis C virus TIBOTEC PHARMACEUTICALS LTD (IE) 2010-02-09 US disclosed
EP-1912981-B1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS TIBOTEC PHARM LTD (IE) 2010-01-20 EP disclosed
EP-1713823-B1 HCV NS-3 SERINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2009-11-11 EP disclosed
US-20090118312-A1 Macrocylic Inhibitors of Hepatitis C Virus JANSSEN SCIENCES IRELAND UC (IE) 2009-05-07 US disclosed
US-20090023758-A1 Macrocyclic Inhibitors of Hepatitis C Virus MEDIVIR AB (SE) 2009-01-22 US disclosed
EP-1881001-A1 HCV NS-3 serine protease inhibitors Tibotec Pharmaceuticals Ltd. (IE) 2008-01-23 EP disclosed
US-20070203072-A1 Hcv Ns-3 Serine Protease Inhibitors MEDIVIR AB (SE) 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023758-A1 Macrocyclic Inhibitors of Hepatitis C Virus CTRC, NOX3, HAVCR2 TLR4 2409/4885KDM4E 4409/4885ALDH1A1 2532/4885
US-20100166706-A1 HCV NS-3 SERINE PROTEASE INHIBITORS HPN, CPN1, PRSS1 TLR4 3769/4885KDM4E 4633/4885ALDH1A1 4292/4885
US-20070203072-A1 Hcv Ns-3 Serine Protease Inhibitors HPN, CPN1, PRSS1 TLR4 3710/4885KDM4E 4614/4885ALDH1A1 4156/4885
US-20090118312-A1 Macrocylic Inhibitors of Hepatitis C Virus CBR1, HAVCR2, AOC1 TLR4 3392/4885KDM4E 4584/4885ALDH1A1 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.